Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Wilms Tumor 6Osteosarcoma 6Neuroblastoma 6Leukemia, Myeloid, Acute 6Glioma 6Rhabdoid Tumor 5Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Hepatoblastoma 5Sarcoma 4Rhabdomyosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Multiple Myeloma 4Medulloblastoma 4Histiocytosis, Langerhans-Cell 4Ependymoma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Sarcoma, Ewing 3Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma 3Lung Neoplasms 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mouth Neoplasms 2Melanoma 2

Interventions

Temozolomide 5Radiotherapy 3Radiation 2Photons 2Magnetic Resonance Spectroscopy 2peposertib 1liposomal doxorubicin 1cemiplimab 1balstilimab 1X-Rays 1Vorinostat 1Utrogestan 1Specimen Handling 1Progestins 1Progesterone 1Perfusion Magnetic Resonance Imaging 1Mycophenolic Acid 1Lomustine 1Irinotecan 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × X-Rays × 30 days × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡